In conclusion, the 2025 CDSCO draft guidelines represent a meaningful and commendable step toward global regulatory alignment in the oversight of biosimilars. The agency has embraced major global ...

While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, ...

Ivo Abraham, PhD, highlights follow-on biologics as a pathway to a more equitable global health care system by reducing costs ...

Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, ...

Australia’s growing reliance on high-cost biologics for inflammatory skin diseases has placed significant pressure on its ...

Number 5: Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening ...